Healthcare Newsletters

Issue

Date

Size

Main Topics

45

March 2017

368 KB

  • Early ART initiation as a factor in combating antibiotic resistance
  • Dolutegravir: not as monotherapy
  • BREATHER - Can HIV+ youth safely have a weekend off their antiretroviral medication?
  • Diagnosing "elite controllers"

44

October 2016

378 KB

  • Rifabutin dosing with protease inhibitors
  • Drug-drug interactions involving second generation NNRTIs
  • Pure Red Cell Aplasia in HIV

43

June 2016

411 KB

  • Dolutegravir: its use in adult patients
  • Dolutegravir: its use in paediatric patients
  • Drug-drug interactions between antiretrovirals and itraconazole
  • Zika and HIV

42

February 2016

194 KB

  • Do elite controllers need ART?
  • Early infant diagnosis of HIV - shifting paradigms
  • Lifelong ART should be offered to ALL HIV-infected patients regardless of CD4 count
  • Pneumococcal vaccination in HIV-infected persons

41

September 2015

444 KB

  • Probiotics and HIV
  • Improved treatment outcomes in patients with XDR TB in South Africa
  • HIV tests in children on ART
  • Management of hyperlipidaemia in patients on protease inhibitors
  • Cross-reactivity between darunavir and co-trimoxazole
  • New 0199 tariff claiming process

40

July 2015

551 KB

  • Rilpivirine (RPV) in pregnancy
  • Is there a need for 6-monthly CD4 monitoring in patients with stable virological suppression on ART?
  • Twitter for the busy Clinician - Opening up a world of HIV-related information
  • The role of micronutrient supplementation in adults

39

March 2015

524 KB

  • HIV-positive-to-HIV-positive renal transplantation
  • Pre-exposure prophylaxis (PrEP): recent findings add to the evidence that it is effective as an HIV prevention tool
  • Use of raltegravir in children
  • Balancing risks and benefits in post exposure prophylaxis

38

November 2014

175 KB

  • Abacavir-based regimens in patients with high viral loads
  • Proton pump inhibitor, H2 receptor blocker and antacid drug interactions with atazanavir/ritonavir
  • Update on the Mississippi child - a reality check
  • Maraviroc
  • A festive reflection

37

August 2014

161 KB

  • The EARNEST trial: new evidence regarding efficacy of second line ART regimens
  • New drug profile: rilpivirine
  • The value of a psychological report in treatment failure
  • Clinical Case Report - 35 year old male patient on a PMB Medical Scheme Option (Subject to State Protocols)

36

December 2013

118 KB

  • Key principles in the management of patients with suspected drug-induced liver injury (DILI) while on TB treatment (with or without ART)
  • The perinatally infected adolescent
  • Rifabutin in HIV medicine
  • Should one discontinue co-trimoxazole prophylaxis in children established on ART?

35

August 2013

131 KB

  • Fixed dose combination antiretrovirals containing TDF, FTC/3TC and efavirenz
  • Combination induction therapy for cryptococcal meningitis
  • Isoniazid preventive therapy for people on ART
  • An approach to weight loss in HIV-infected patients
  • World Health Organization raises the bar

34

April 2013

165 KB

  • Etravirine
  • Potential Cure of HIV in an infant - The Mississippi child - What can we learn? Can we already change our practice?
  • Use of Pre-Exposure Prophylaxis
  • 20th Conference on Retroviruses and Opportunistic Infections

33

December 2012

217 KB

  • Practice Point - "Lipodystrophy" due to an unexpected drug interaction
  • Timing of ART in patients with cryptococcal meningitis
  • Abacavir or Tenofovir in 1st line ART?
  • A Festive Reflection

32

June 2012

126 KB

  • National Department of Health Guidelines on the Management of Drug-resistant TB
  • Study of switching to atazanavir for lipodystophy
  • Reporting Adverse Drug Reactions
  • Tenofovir for children and adolescents

31

February 2012

121 KB

  • The conundrum of infant feeding for HIV infected women continues
  • Tenofovir and aminoglycosides
  • What if my patient's CD4 count does not rise on ART
  • Isoniazid preventive therapy

30

November 2011

126 KB

  • Managing fat gain in patients on antiretroviral therapy
  • TB treatment in patients on second-line ART
  • Lopinavir/ritonavir and Congenital Adrenal Hyperplasia in exposed infants?
  • Developments in HIV renal transplantation
  • Report back from the Mind, Body, HAART Symposium - Integrating mental health into HIV care

29

June 2011

111 KB

  • ART for Prevention
  • Cryptococcal Antigen Screening in Patients with CD4 <= 100

28

May 2011

121 KB

  • Efavirenz Dose for Paediatric Patients
  • Raltegravir: What is the Place of the New Kid on the Block?
  • When is the Optimal Time to Start ART in Patients with TB? Recent findings
  • African RCT of Influenza Vaccination in HIV Shows Benefit and Safety

27

December 2010

121 KB

  • Pre-exposure prophylaxis
  • CD4 counts and percentages in children
  • ART resistance, genotype resistance testing and archiving
  • Amphotericin B

26

October 2010

121 KB

  • Patients with poor adherence to first line ART (2 NRTIs + 1 NNRTI) who have a persistently non-suppressed viral load
  • Antimalarial chemoprophylaxis and treatment
  • Newer protease inhibitors do not cause diabetes

25

July 2010

161 KB

  • Single drug switch from stavudine (or zidovudine) to tenofovir
  • Long term isoniazid preventive therapy for HIV-infected adults: new evidence
  • Immunization and HIV in adults
  • Immunization in HIV-infected children and adolescents - emerging perspectives in 2010

24

February 2010

173 KB

  • HIV and pandemic influenza; lessons learnt and what to expect?
  • Differential Diagnoses to consider in a patient with suspended TB
  • Using nevirapine-based are in patients with TB
  • Use of Ritonavir(Norvir®) as single protease infibitor in fants and childern
  • Discontinuation Notice: Kaletra® soft gel capsules

23

October 2009

168 kb

  • When is the best time to start antiretroviral therapy?
  • Elective caesarean sections and HIV transmission
  • Genotyping testing for antiretroviral resistance
  • Use of STAVUDINE(D4T) as part of combination therapy
  • Antibiotics to prevent STIs POST SEXUAL ASSAULT

22

April 2009

167 kb

  • Antiretrovirals and the liver
  • Isoniazid (INH) prophylaxis for HIV-infected children
  • Isoniazid preventive therapy for HIV-infected healthcare workers
  • Risk factors for nephrotoxicity in patients on tenofovir
  • Zidovudine (AZT) dose adjustment for infants
  • Pneumonia in patients with HIV infection

21

January 2009

429 kb

  • Abacavir and the risk of myocardial infarction
  • New insights in infant feeding – breast versus formula
  • New Southern African HIV Clinicians Society Guidelines for Postexposure Prophylaxis
  • Switching antiretrovirals for lipodystrophy

20

June 2008

209 kb

  • Antiretroviral therapy and the risk of myocardial infarction
  • Aluvia tablets replace Kaletra
  • Diagnosis of Mycobacterium Avium Complex (MAC) infection
  • TDF (Tenofovir Disporoxil Fumarate) in special situations
  • Antiretroviral resistance testing (genotyping)

19

February 2008

212 kb

  • Aid for AIDS Clinical Newsletter – Issue 19
  • Double-boosted protease inhibitor therapy for salvage ART: lack of evidence of benefit
  • Diagnosing and treating smear negative and extrapulmonary Tuberculosis in HIV-infected patients
  • Atazanavir in pregnancy
  • Fluconazole and pregnancy
  • Nutritional Management of the HIV positive patient “facts, fallacies and folk-lore”
  • Monitoring patients on tenofovir – an update
  • Completing the AfA application form

18

November 2007

html

  • Atazanavir
  • Resistance mutations and atazanavir
  • Early antiretroviral therapy (ART) in infants
  • Hepatotoxicity when using adjusted dose Kaletra® with rifampicin
  • Clinical, virological and immunological responses to HAART
  • NNRTI vs boosted PI regimens

17

July 2007

146 KB

  • The use of Tenofovir Disoproxil Fumarate (TDF) in HAART regimens
  • Resistance patterns associated with decreased tenofovir efficacy
  • Emtricitabine (FTC)
  • Tenofovir: Side effects and toxicities
  • Hepatitis B
  • The use of tenofovir in pregnancy and in paediatric patients
  • Monitoring patients on tenofovir
  • Viread® and Truvada®
  • Tenofovir drug interactions

16

March 2007

110 KB

  • Contraception and antiretroviral therapy
  • Monitoring lipids and glucose
  • The SMART study
  • Breast feeding in HIV-infected and exposed infants - paradigm shift
  • Antiretroviral therapeutic drug monitoring
  • Monitoring and promoting adherence to therapy with courier pharmacies

15

December 2006

14 KB

  • Dose of Stavudine
  • Patients who Switch to Nevirapine with Higher CD4 Counts are not at Increased Risk of Hepatotoxicity
  • Antiretroviral Resistance Testing
  • Routine Testing for HIV Infection
  • Post Exposure Prophylaxis (PEP) - Remember to Assess the Risks and Benefits
  • Pneumococcal Vaccine for Children

14

June 2006

15 KB

  • Pro Forma Letter

14

June 2006

115 KB

  • Breastfeeding in HIV-Infected Infants
  • Triomune-40 Tablets are Available
  • Referring Patients to Public Sector ARV Clinics
  • Bacterial Pneumonia in HIV+ Adults
  • Using Kaletra with Rifampicin

13

January 2006

126 KB

  • AfA awarded the HIV Disease Management contract for GEMS
  • Discontinuing fluconazole prophylaxis following cryptococcal meningitis
  • Tenofovir plus didanosine (DDI)
  • Switching stavudine (D4T) to an alterative agent

12

October 2005

146 KB

  • Management of Patients with Myperlactataemia / Lactic Acidosis
  • Doses in Renal Failure
  • Enteric Coated Videx Capsules Available
  • HAART Hypertension

11

June 2005

59 KB

  • New AfA guidelines for initiating HAART in adults
  • Management of isolated elevated Gamma Glutamyl Transpeptidase (GGT) levels in HIV
  • WHO Clinical Stage III and IV conditions
  • Treating PCP in patients who are allergic to Cotrimoxazole
  • AfA Clinical Guildelines - 5th Edition

10

February 2005

71 KB

  • Management of HIV - Associated Kaposi's Sarcoma (KS)
  • Generic Antiretrovirals ARVs)
  • Scheme changes for 2005
  • FDA Public Health Advisory for Nevirapine

9

August 2004

62 KB

  • WHO clinical staging
  • The role of Tenofovir DF (Viread)
  • Protease inhibitor induced diarrhoea
  • Benefit booking
  • Making major decisions on CD4+ counts
  • Tuberculosis and ART
  • Generic antiretrovirals

8

April 2004

71 KB

  • Nevirapine and pregnancy - new concerns
  • Immune "boosters" in HIV infection
  • AfA and generic antiretroviral agents
  • Increase in 0199 payment
  • Scheme changes for 2004
  • Kaletra and Rifampicin
  • HAART and Porphyria

7

November 2003

59 KB

  • Voluntary Counselling and Testing
  • Non-nucleoside reverse transcriptase inhibitor in the internal regimen
  • AfA and generic antiretroviral agents
  • Death knell for structured treatment interruptions
  • The Medscheme Price List (MPL)

6

August 2003

78 KB

  • New AfA criteria for initiating ART
  • Pharmaceutical Courier Services
  • ICU management of HIV patients
  • HIV rapid testing

5

March 2003

55 KB

  • The role of nelfinavir (Vira-cept)
  • Changing from dual NRTI therapy to HAART
  • Guidelines for managing Lipid disorders
  • Structured treatment interruptions

4

December 2002

81 KB

  • New guidelines for initiating Antiretroviral Therapy (ART)
  • Scheme changes for 2003
  • Corrections to the 4th edition of the Clinical guidelines

3

September 2002

61 KB

  • CD4 counts for dummies
  • Mother-to-Child prophylaxis

2

March 2002

60 KB

  • HIV VIral loads for dummies
  • Peripheral neuropathy
  • Dealing with Cotrimoxazole intolerance

1

August 2001

65 KB

  • Tuberculosis and antiretroviral therapy
  • Testing for resistance to HIV drugs
  • Intensifying antiretroviral therapy

patient care line
0860 100 646

doctor/pharmacist
0800 227 700

cape town office
+27 (0)21 466 1700

fax
0800 600 773
+27 (0)21 466 1771

Email Address afa@afadm.co.za